Clinical Impact of Peridevice Leak Following Left Atrial Appendage Closure

Left atrial appendage closure (LAAO) has consolidated as a valid strategy for thromboembolic event prevention in patients with non-valvular atrial fibrillation (NVAF), especially in patients with oral anticoagulation contraindication. 

However, the presence of peridevice leak (PDL) following LAAO has raised questions about its long term clinical impact. 

The OCEAN-LAAC, a Japanese multicenter study, prospectively looked at PDL repercussion by transesophageal EKG immediately after procedure and during clinical followup. This analysis focused mainly on leaks deemed “acceptable” (≤3 mm).  

The primary outcome was incidence of thromboembolic events – transient ischemic attack (TIA), ischemic stroke or systemic embolization – within two years after procedure. Secondary end point was all cause mortality at 2 years. 

Read also: Evolution of Renal Denervation at 24 Months.

Data from 1397 patients were analyzed. 6% presented PDL, mean patient age was 77.5, and they were mostly men; mean CHA₂DS₂-VASc score was 4 and HAS-BLED was 3. PDL was observed mostly in patients with elevated baseline heart rate, larger LAA ostial diameter and in most Watchman 2.5 devices, vs FLX.

Ischemic event incidence was significantly higher in patients with any PDL (Gray’s Test, p=0.0036), including those ≤3 mm (sHR: 3.53; CI95%: 1.37–9.04; p=0.016). Altogether, data show the presence of PDL is associated with nearly four times more ischemic events (sHR: 4.25; CI95%: 1.91–9.44; p<0.001).

However, this increase of thromboembolic events does not translate into higher global mortality, probably because of the non-fatal nature of many TIA and ischemic strokes, as well as timely intervention. 

Conclusion

These results suggest that leaks detected after procedure, including those deemed acceptable in size, might have relevant clinical impact on patient prognosis. 

Original Title: Impact of Peridevice Leak on Clinical Outcomes After Left Atrial Appendage Closure: The OCEAN-LAAC Registry.

Reference: Saito T, Tsuruta H, Kajino A, Iwata J, Sakata S, Ryuzaki T, Sago M, Tanaka S, Chatani R, Hachinohe D, Naganuma T, Ohno Y, Tani T, Okamatsu H, Mizutani K, Watanabe Y, Izumo M, Saji M, Mizuno S, Ueno H, Kubo S, Shirai S, Nakashima M, Asami M, Yamamoto M, Ieda M, Hayashida K; OCEAN‐LAAC investigators. Impact of Peridevice Leak on Clinical Outcomes After Left Atrial Appendage Closure: The OCEAN-LAAC Registry. J Am Heart Assoc. 2025 Aug 18:e044422. doi: 10.1161/JAHA.125.044422. Epub ahead of print. PMID: 40820980.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...